LabGenomics Exclusively Supplies COVID-19 Diagnostic Kits to Siemens Healthineers... "Targeting the Indian Market"

[Asia Economy Reporter Minji Lee] LabGenomics, a molecular diagnostic healthcare specialist company, announced on the 24th that it will supply COVID-19 diagnostic kits to the Indian market in partnership with Siemens Healthineers. To this end, the company became the first domestic firm to complete registration with the Indian FDA and obtain import item approval.

Siemens Healthineers, collaborating with the company, is a leading German medical technology firm. It leads the core product and service portfolio across major medical industries, including diagnostic imaging, therapy, imaging, diagnostic testing, and molecular diagnostics, and shares the global diagnostic market with Roche.

The company will exclusively supply COVID-19 diagnostic kits to Siemens Healthineers' Indian subsidiary, and Siemens Healthineers plans to distribute them in the Indian market. The initial shipment volume is 100,000 tests.

India, with a population of approximately 1.3 billion, operates 65 national and public hospitals and 50 certified testing centers. Due to the spread of COVID-19, health authorities are working to secure additional testing centers, which is expected to increase sales of the COVID-19 diagnostic kits supplied by the company.

A company representative stated, “This is an opportunity to diversify overseas sales channels through collaboration with a multinational diagnostic company,” adding, “We plan to strengthen our sales capabilities in regions outside India by utilizing the distribution network owned by Siemens Healthineers.”

This content was produced with the assistance of AI translation services.